EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Notch3/4 Knockdown Inhibits Colon Adenocarcinoma Progression by Suppressing Tumor Cell Activity and Orchestrating VEGFA ‐Dependent Tumor Immune Microenvironment

Wei Liu, Guhang Tang, Ningfu Li, Jiasheng Wang, Han Zhao, Chong Li iD

Cancer Medicine · 2026-07 · 15 (7)

DOI: 10.1002/cam4.72121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 15.07.2026. Verfasst von Wei Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Dazu's Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Receptor, Notch3, Receptor, Notch4, Tumor Microenvironment, Colonic Neoplasms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colon adenocarcinoma (COAD) is a prevalent gastrointestinal malignancy characterized by dysregulation of multiple cellular signaling pathways, including the Notch pathway. However, the specific biological roles of Notch3 and Notch4 in COAD remain incompletely characterized.

Methods

We aimed to investigate the effects of Notch3 and Notch4 downregulation on the tumor immune microenvironment and angiogenesis in COAD. Using a combination of in vitro and in vivo models, we evaluated the impacts of Notch3/4 interference on cell proliferation, migration, immune cell infiltration, and tumor progression.

Results

Interfering with Notch3 and 4 significantly suppressed subcutaneous tumor progression. Notably, this inhibition was not only associated with reduced cell viability, but also with an altered immune environment characterized by enhanced macrophage M1 polarization and T lymphocyte activation, which may be linked to the c‐Myc/VEGFA signaling axis but requires further mechanistic validation. Furthermore, the combination of regorafenib and Notch3/4 knockout (KO) exerted enhanced anti‐tumor effects. More importantly, Mol_2, a candidate compound with predicted binding affinity for both Notch3 and Notch4, was screened out to significantly reduce the protein levels of Notch3 and Notch4 and tumor progression.

Conclusions

Our findings suggest that targeting Notch3 and Notch4 receptors may have therapeutic potential for modulating the tumor microenvironment and suppressing tumor progression in COAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Notch3Receptor, Notch4Tumor MicroenvironmentColonic NeoplasmsAdenocarcinomaVascular Endothelial Growth Factor AAnimalsHumansMiceCell ProliferationDisease ProgressionCell Line, TumorSignal TransductionCell MovementGene Knockdown TechniquesGene Expression Regulation, NeoplasticNeovascularization, PathologicMale

Stichwörter der Autor:innen

colon adenocarcinoma (COAD)notch3notch4tumor microenvironment (TME)

Substanzen

Receptor, Notch3Receptor, Notch4NOTCH4 protein, humanNOTCH3 protein, humanVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Oncology, The Affiliated Dazu's Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan, China.

ORCID-Profile: Chong Li

Zitieren

APA

Liu, W., Tang, G., Li, N., Wang, J., Zhao, H., & Li, C. (2026). Notch3/4 Knockdown Inhibits Colon Adenocarcinoma Progression by Suppressing Tumor Cell Activity and Orchestrating VEGFA ‐Dependent Tumor Immune Microenvironment. Cancer Medicine, 15(7). https://doi.org/10.1002/cam4.72121

Vancouver

Liu W, Tang G, Li N, Wang J, Zhao H, Li C. Notch3/4 Knockdown Inhibits Colon Adenocarcinoma Progression by Suppressing Tumor Cell Activity and Orchestrating VEGFA ‐Dependent Tumor Immune Microenvironment. Cancer Medicine. 2026;15(7). doi:10.1002/cam4.72121

BibTeX
@article{Liu2026,
  author = {Liu, Wei and Tang, Guhang and Li, Ningfu and Wang, Jiasheng and Zhao, Han and Li, Chong},
  title = {Notch3/4 Knockdown Inhibits Colon Adenocarcinoma Progression by Suppressing Tumor Cell Activity and Orchestrating VEGFA ‐Dependent Tumor Immune Microenvironment},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.1002/cam4.72121}
}
Kostenlos starten →